What Candid Health Announced About Its 120 Million Dollar Series D
Candid Health said on 22 July 2026 that it raised 120 million dollars in a Series D round led by Sixth Street Growth, with Oak HC/FT, 8VC and Y Combinator taking part, and that the round valued the company at three times its February 2025 Series C. The company reports 190 percent year-over-year annual contracted run-rate revenue growth and 180 percent year-over-year net dollar retention in 2025, says it serves more than 200 healthcare organisations, and frames the opportunity as the 280 billion dollars spent each year on revenue cycle management in the United States.
Why the Candid Health Series D Matters to Billing Buyers
Net dollar retention of 180 percent means existing customers are spending far more each year, which is the strongest signal in this list because it is harder to manufacture than new sales. It also means the business model depends on expanding inside accounts, so a buyer should expect upsell pressure and should fix scope and pricing for more than one year. The 280 billion dollar figure is a market size, not a saving, and nothing here says what a single practice collects.
Where the Candid Health Update Comes From
Candid Health is the original record behind this update. It tells us what the company published. This brief adds the market context and the method we would use to test the development against other evidence.
Candid Health original source.
How We Would Research the Candid Health Series D
The source gives us the starting point. This is how we would build the next layer of research around it.
- We would ask what net dollar retention means in their definition, since expansion revenue can include volume growth a practice would have had anyway.
- Then we would ask for the churn number alongside it, because retention of 180 percent can sit beside real customer losses.
- We would price a three-year contract rather than one, given a growth-funded vendor has every reason to raise rates at renewal.